ProMIS Neurosciences Announces Trading on OTCQB Venture Market

                                                                                                         

TORONTO, Ontario and CAMBRIDGE, Massachusetts, December 4, 2017 – ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its common shares have been approved for trading on the OTCQB® Venture Market (OTCQB) in the United States under the symbol “ARFXF”. OTCQB is a U.S. trading platform operated by the OTC Markets Group in New York.  ProMIS Neurosciences common shares will continue to trade on the Toronto Stock Exchange (TSX:PMN).

“We are pleased to announce our new trading relationship with the OTCQB.  As part of our ongoing strategy to introduce ProMIS to a broader international audience, this milestone will provide greater visibility, better access to the U.S. investment community, and improved convenience of trading the Company's common shares,” said Elliot Goldstein, M.D., ProMIS President and CEO.

The OTCQB Venture Market is for early-stage and developing U.S. and international companies. To be eligible, companies must be current in their financial reporting, pass a minimum $0.01 bid price test and undergo an annual company verification and management certification process. The OTCQB quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors.

 

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a development stage biotech company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets, known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company’s website at:  www.promisneurosciences.com

Follow us on Twitter

Like us on LinkedIn

 

For media inquiries, please contact:

Scott Santiamo

RussoPartners/LLC

Scott.Santiamo@russopartnersllc.com

Tel. 718 344-5843

 

David Schull

RussoPartners/LLC

David.Schull@russopartnersllc.com

Tel. 858 717-2310

 

For Investor Relations please contact:

Alpine Equity Advisors

Nicholas Rigopulos, President

nick@alpineequityadv.com

Tel. 617 901-0785

 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com

 

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

This news release contains certain “forward-looking statements” within the meaning of Canadian securities legislation, relating to the commencement of trading of the common shares and warrants of the Company and the composition of the Company’s board of directors following the Meeting. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause future results to differ materially from those anticipated in these forward-looking statements include, but are not limited to, the Company’s inability to secure shareholder approval required to approve the matters to come before shareholders at the Meeting.

 



ProMISTM Neurosciences, Inc.

 

NEWS RELEASE TSX: PMN

FOR IMMEDIATE RELEASE

 

ProMIS Neurosciences Announces Third Quarter 2017 Results

 

TORONTO, Ontario and CAMBRIDGE, Massachusetts November 13, 2017 – ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results for the three and nine months ended September 30, 2017.

 

Commenting on the update, Elliot Goldstein, M.D., ProMIS President and CEO stated: “With the successful private placement in Q3 2017 supporting a cash runway into the second half of 2018, we continue to focus on the company’s top priorities.  In this regard, we look forward to further advancing the development of our lead product candidates for Alzheimer’s disease with particular emphasis on the ongoing preclinical program to differentiate our leads compared to competitive antibody products in development. We remain confident that our monoclonal antibody program focused on selectively targeting the toxic, prion-like forms of amyloid beta may lead to best in class therapies and significant long-term value creation.”

 

 

Recent Corporate Highlights

 

·      In August 2017, the Company completed a brokered private placement offering (the Offering) through the issuance of 19,164,306 units at a price of $0.25 per unit for gross proceeds of $4,791,076 ($4,142,465 net of issuance costs). Each Unit consists of one common share and one-half of a common share purchase warrant.  The issued common shares are subject to a four-month hold period from the date of issuance.  Each whole warrant is exercisable into one share at a price of $0.30 per share for a 60-month exercise period.

 

·      On September 13, 2017, the Company announced a significant development milestone by demonstrating that PMN330, directed against a different target on toxic amyloid beta oligomers (AbO) compared to PMN310 and PMN350, also displays an optimal target product profile of selective binding to toxic AbO. PMN330 was designated third validated lead product candidate having demonstrated in vivo data and biologic evidence of neuronal protection against toxic AbO.

 

·      In Q3 2017 the Company initiated its preclinical program to evaluate the potential best in class profile of PMN310, PMN350 and PMN330 in direct comparison to other antibodies targeting amyloid beta.

 

·      In Q3 the Company generated monoclonal antibodies against a recently identified epitope target on TDP43 for ALS and frontotemporal dementia and initiated preclinical evaluation.

·      Using the ProMIS proprietary discovery platform the Company is pursuing identification of specific targets on alpha synuclein (Parkinson’s disease and Lewy body dementia) and tau (Alzheimer’s disease, other dementias).

 

Financial Results

Results of Operations – Three months ended September 30, 2017 and 2016

The net loss for the three months ended September 30, 2017 was $1,618,681, compared to a net loss of $859,371 for the three months ended September 30, 2016.  The increased loss in the current period reflects the costs associated with operating the Company’s AD therapeutics program, supporting its patent portfolio, associated general corporate expenditures and higher stock-based compensation.  

For the three months ended September 30, 2017, the Company recognized $9,008 in royalty revenue related to its preclinical AD diagnostic assay as compared to $0 for the three months ended September 30, 2016.

Research and development expenses for the three months ended September 30, 2017 were $1,317,893 as compared to $492,717 in the three months ended September 30, 2016.  Costs are higher in the current period due to higher research program costs for the AD therapeutics program and increased headcount. 

General and administrative expenses for the three months ended September 30, 2017 were $307,533 as compared to $366,654 in the three months ended June 30, 2016.  The decreased expenditures in the current period reflect Foreign exchange gain on USD denominated expenses and decreased legal and professional fees, offset by higher investor relations expenses and higher salaries related to expansion of the senior management team. 

Results of Operations – Nine months ended September 30, 2017 and 2016

The net loss for the nine months ended September 30, 2017 was $4,894,280, compared to a net loss of $2,243,874 for the nine months ended June 30, 2016.  The increased loss in the current period reflects the costs associated with operating the Company’s AD therapeutics program, supporting its patent portfolio, associated general corporate expenditures and higher stock-based compensation.  

For the nine months ended September 30, 2017, the Company recognized $9,666 in royalty revenue related to its preclinical AD diagnostic assay as compared to $2,486 for the nine months ended September 30, 2016.

Research and development expenses for the nine months ended September 30, 2017 were $3,303,962 as compared to $1,169,228 in the nine months ended September 30, 2016.  Costs are higher in the current period due to higher research program costs for the AD therapeutics program, supporting its patent portfolio and increased headcount 

General and administrative expenses for the nine months ended September 30, 2017 were $1,592,881 as compared to $1,063,710 in the nine months ended September30, 2016.  The increased expenditures in the current period reflect higher investor relations expenses, higher salaries related to expansion of the senior management team, higher professional fees, and higher stock-based compensation offset by foreign exchange gain on USD denominated expense and reduced legal expenses. 

 

Outlook

The Company’s priorities for the next year are to identify and develop precision medicine therapeutics for Alzheimer’s disease (AD) and ALS.

The Company’s plan is to further advance its AD portfolio, with a focus on competitive differentiation versus other antibody therapies in development for AD that target amyloid beta. Furthermore, the Company plans to continue on-going development of effective AD diagnostics for detection of toxic prion strains targeted by ProMIS antibody therapeutic candidates in either cerebrospinal fluid or blood. Technology refinement and optimization are ongoing to create highly sensitive assays for this purpose.

The Company will continue to expand its intellectual property estate relating to novel epitope targets and antibodies targeting toxic forms of tau for AD, misfolded forms of  TDP43 for ALS and  toxic strains of alpha synuclein for Parkinson’s disease. The Company’s complementary proprietary platform technologies, ProMISTM and Collective Coordinates, will be employed to identify and confirm such novel targets.

 

About ProMIS Neurosciences, Inc.

 

ProMIS Neurosciences is a Toronto Stock Exchange (TSX) listed biotechnology company (trading symbol: PMN.TO), headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. The Company's mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The Company’s   proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets, known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS.

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

For further information please consult the Company's website at:

www.promisneurosciences.com

 

Follow us on Twitter
Like us on 
LinkedIn

 

For media inquiries, please contact:

 

Scott Santiamo
RussoPartners/LLC
Scott.Santiamo@russopartnersllc.com
Tel. 718 344-5843

 

David Schull

RussoPartners/LLC

David.Schull@russopartnersllc.com

Tel. 858 717-2310

 

For Investor Relations please contact:

 

Alpine Equity Advisors

Nicholas Rigopulos, President

nick@alpineequityadv.com

Tel. 617 901-0785

 

 

 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com

 

 

 

 

 



 

ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer's Disease

Narrated presentation of results available on ProMIS website

TSX: PMN

TORONTO and CAMBRIDGE, MAOct. 17, 2017 /PRNewswire/ - ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its lead product candidate for Alzheimer's disease, PMN310, showed the desired binding profile of selectively targeting amyloid beta oligomers in a preclinical study directly comparing PMN310 to other amyloid beta-directed antibodies for Alzheimer's disease (AD).

ProMIS Neurosciences Inc. (CNW Group/ProMIS Neurosciences Inc.)

A narrated presentation of these results is available on the ProMIS Neurosciences website at: http://bit.ly/2gp8S4t

Commenting on these results, ProMIS President and CEO, Elliot Goldstein, MD, stated: "We are pleased to confirm the selective binding of PMN310 to amyloid beta oligomers, a root cause of Alzheimer's disease. Results of prior clinical studies with other amyloid beta antibody therapeutics clearly showed that antibodies targeting amyloid beta monomer have consistently been ineffective, while those targeting amyloid beta fibrils, the main component of plaque, are associated with a dose limiting toxicity of brain swelling. Taken together, results of prior clinical trials indicate the best in class target product profile is selective binding of toxic amyloid beta oligomers."

The binding profile of PMN310 was compared to that of other candidate antibody therapeutics for AD in a preclinical study using the "dot blot" technique. Results of the study showed that PMN310 selectively binds amyloid beta oligomers (AbO), with virtually no binding to the other forms of amyloid beta. By comparison, solanezumab (Eli Lilly) showed binding mainly to Ab monomers; bapineuzumab (Johnson & Johnson/Pfizer, discontinued) showed binding to all forms of Ab (monomers, fibrils, oligomers); and aducanumab (Biogen) showed preferential binding to fibrils and oligomers.

Dot blotting is a method of applying (dotting) proteins, such as Ab monomers, fibrils and oligomers, directly onto a membrane or other support. Samples of the antibody to be evaluated are then applied and the binding pattern to the various forms of amyloid beta can be observed.

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a Toronto Stock Exchange listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario with offices in Cambridge, Massachusetts. The Company's mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.

ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company's website at: 
www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

 

SOURCE ProMIS Neurosciences Inc.



ProMIS Neurosciences Provides Third Quarter Update for 2017

Updated corporate overview available on ProMIS website

TSX: PMN

TORONTO and CAMBRIDGE, MAOct. 11, 2017 /PRNewswire/ - ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today provided a corporate update for the third quarter of 2017, including key accomplishments and a status update on ongoing programs.

ProMIS Neurosciences Inc. (CNW Group/ProMIS Neurosciences Inc.)

A narrated corporate overview of third quarter 2017 progress is available on the ProMIS Neurosciences website at: http://bit.ly/2xuss6Q

 Key accomplishments in the third quarter of 2017 and near-term value drivers include:

  • Closed second and final tranche of private placement, raising aggregate gross proceeds of approximately CDN $4,800,000
  • Successful humanization of lead product candidate PMN310 for Alzheimer's disease 
    • PMN310 on track for 2019 initiation of clinical trials
  • Expansion of potential best in class portfolio selectively targeting toxic Amyloid beta oligomers (AβO) for Alzheimer's disease
    • Designated PMN330 as third validated lead product candidate demonstrating in vivo data and biologic evidence of neuronal protection against toxic AβO
    • Initiated humanization of PMN330 and PMN350
  • Preclinical program initiated to confirm best in class profile of PMN310, PMN350 and PMN330 in direct comparison to other antibodies targeting amyloid beta
  • Cohort study progress
    • Technology refinement and optimization ongoing to create highly sensitive assays for detection of AβO targets in cerebrospinal fluid (CSF)
  • Recognition and visibility at major international meetings
    • Oral presentation and session chair at Alzheimer's Association International Conference, London, UK, July, 2017
    • Oral presentation at Third Annual R&D Technologies Conference, London, UK, September, 2017
  • Progress relating to multiple neurodegenerative diseases
    • Generated monoclonal antibodies against a recently identified epitope target on TDP43 for ALS and frontotemporal dementia and initiated preclinical evaluation.
    • Ongoing work using ProMIS proprietary discovery platform to identify specific targets on alpha synuclein (Parkinson's disease and Lewy body dementia) and tau (Alzheimer's disease, other dementias)

 

Commenting on the update, ProMIS Executive Chairman Eugene Williams stated: "Our Alzheimer's disease program continues to make significant progress. With respect to drug development, our priorities for this program are twofold: to drive PMN310 to clinical trial initiation in 2019 and importantly, to further differentiate our Alzheimer's product candidates as best in class in direct comparison to other antibody treatments targeting Amyloid beta. With respect to our research programs, we are pleased with the progress made using our proprietary discovery engine to identify novel targets for multiple neurodegenerative diseases."

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a Toronto Stock Exchange listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario with offices in Cambridge, Massachusetts. The Company's mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.

ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE
ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference

Presentation highlights the use ProMIS’ proprietary discovery platform to identify novel therapeutic targets on misfolded proteins in multiple neurodegenerative diseases

TORONTO, Ontario and CAMBRIDGE, Massachusetts – September 28, 2017– ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, announced that Neil Cashman, MD, Professor and Canada Research Chair, University of British Columbia and Chief Scientific Officer, ProMIS Neurosciences, will present today at the 3rd Annual Neuroscience R&D Technologies Conference: Exploring Cutting-edge Technologies in Pre-clinical Neuroscience  Studies.

Dr. Cashman’s presentation, entitled Misfolding Proteins in Neurodegenerative Diseases describes the roles of toxic misfolded proteins as underlying drivers of multiple neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). 

Commenting on the presentation, Eugene Williams, ProMIS Executive Chairman, stated, “We are delighted with the international recognition Neil Cashman is receiving for his important work in neurodegenerative diseases. Using ProMIS’ proprietary discovery platform across a range of neurodegenerative diseases, Dr. Cashman and our team have identified novel therapeutic targets on toxic misfolded proteins, including Amyloid beta oligomers in Alzheimer’s disease, TDP43 in ALS, and alpha synuclein in Parkinson’s disease. Antibodies selectively binding these novel targets, such as ProMIS’ validated lead product candidate for Alzheimer’s disease, PMN310, offer an exciting approach to the development of potential best-in-class therapeutics.”

The 3rd Annual Neuroscience R&D Technologies Conference, to be held in London, UK, September 28-29, 2017, is focused on sharing current market trends, technological advancements, and future challenges in pre-clinical neuroscience research. The conference gathers leading experts from the pharmaceutical industry and research institutes to evaluate the latest technologies in neuroscience R&D with expert keynote presentations, live case studies, and breakthrough panel discussions. 

About ProMIS Neurosciences, Inc. 

ProMIS Neurosciences is a TSX listed biotechnology company (trading symbol: PMN.TO), headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts. The mission of ProMIS is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS. 

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique “precision medicine” approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target. 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

For further information please consult the Company’s website at: 

www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

 

For media inquiries, please contact:

 

Scott Santiamo
RussoPartners/LLC
Scott.Santiamo@russopartnersllc.com
Tel. 718 344-5843

 

David Schull

RussoPartners/LLC

David.Schull@russopartnersllc.com

Tel. 858 717-2310

 

For Investor Relations please contact:

Alpine Equity Advisors

Nicholas Rigopulos, President

nick@alpineequityadv.com

Tel. 617 901-0785

 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Elliot.goldstein@promisneurosciences.com

Tel. 415 341-5783



 

ProMIS Neurosciences Independent Director Anthony J. Giovinazzo Recognized with Inaugural Bloom Burton Award for Innovation in Canadian Healthcare

TORONTO, ONTARIO and CAMBRIDGE, MA – September 21, 2017 – ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that Independent Director Anthony J. Giovinazzo was recently bestowed the inaugural Bloom Burton Award for his extraordinary impact on Canada’s innovative healthcare industry.

Mr. Giovinazzo was recognized for pioneering the development of Cynapsus Therapeutics Inc. and its therapy for managing debilitating OFF episodes associated with Parkinson’s disease. Under Mr. Giovinazzo’s leadership, Cynapsus was acquired by Sunovion Pharmaceuticals Inc. in a 2016 transaction that was much-heralded among the Canadian biotechnology industry.  

“I am deeply honored to be recognized with the inaugural Bloom Burton Award for my impact on the Canadian healthcare industry,” said Mr. Giovinazzo. “The Cynapsus exit to Sunovion was a seminal transaction in Canada and continues to represent the innovative spirit of our life sciences community. I sincerely thank Brian Bloom and Jolyon Burton for their leadership in this field and the esteemed independent judges panel for such a distinguished honor.”

The Bloom Burton Award is overseen by Bloom Burton & Co., Canada’s leading healthcare-specialized investment banking firm. The annual award honors an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest impact in Canada’s innovative healthcare industry. Nominees are accepted from the biotechnology, pharmaceutical, medical device, diagnostic/imaging, research instrumentation, consumer health, healthcare services or healthcare IT sectors, and from all therapeutic indications and stages of development.

“We congratulate Anthony for receiving such recognition for his work. We also look forward  to his continuing support as a member of the ProMIS Board of Directors as we fulfill our mission to discover and development best-in-class precision therapeutics for the treatment of neurodegenerative diseases,” stated ProMIS Executive Chairman Eugene Williams.

The Bloom Burton Award finalists and winner are chosen by an esteemed panel of judges, all of whom are respected international leaders in healthcare investment, entrepreneurship and journalism. The panel includes: Karen Bernstein, Co-Founder and Chairman, BioCentury Inc.; Terrence Connolly, Executive Director, Global Alliances and Business Development, Celgene Corporation; Carl Gordon, Partner and Co-Head of Global Private Equity, OrbiMed Advisors; Andrew Hack, Chief Financial Officer, Editas Medicine; Oleg Nodelman, Founder and Managing Director, EcoR1 Capital; Melinda Richter, Head of Johnson & Johnson Innovation, JLABS; and Avik Roy, Opinion Editor, Forbes; President, The Foundation for Research and Equal Opportunity.

On October 21, 2016, Sunovion Pharmaceuticals Inc. completed the acquisition of Cynapsus Therapeutics. Sunovion is an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd.

 

About ProMIS Neurosciences, Inc.

 

ProMIS Neurosciences is a Toronto Stock Exchange (TSX) listed biotechnology company (trading symbol: PMN.TO), headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. The Company's mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets, known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The Company owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS and currently has a preclinical monoclonal antibody therapeutic against this target.

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information, including about the timing and completion of the Offering, the receipt of TSX approval and the expected use of proceeds from the Offering. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

For further information please consult the Company's website at:

www.promisneurosciences.com

 

Follow us on Twitter
Like us on 
LinkedIn

 

For media inquiries, please contact:
RussoPartners/LLC
Scott.Santiamo@russopartnersllc.com
Tel. 718 344-5843

 

David Schull

RussoPartners/LLC

David.Schull@russopartnersllc.com

Tel. 858 717-2310

 

For Investor Relations please contact:

Alpine Equity Advisors

Nicholas Rigopulos, President

617-901-0785

nick@alpineequityadv.com

 

 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com

 

 

 

 

 

 

 

 

 

 

 



 

ProMIS Neurosciences Announces Successful Humanization of Lead Product Candidate PMN310 for Alzheimer’s Disease  

 Clinical trials evaluating PMN310 expected to initiate in 2019

 

TORONTO, Ontario and Cambridge, Massachusetts – September 19, 2017 – ProMIS Neurosciences, Inc., a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced the successful humanization of its lead product candidate for Alzheimer’s disease (AD), PMN310, a monoclonal antibody (mAb) targeting toxic prion-like forms of amyloid-beta oligomers (AβO).

 “We have now completed a significant development milestone by producing a humanized version of PMN310 and, in the process, achieving a ten-fold increase in binding affinity for its conformational target on toxic AβO,” stated Neil Cashman, MD, ProMIS’ Chief Scientific Officer. ”This increased affinity of PMN310, along with its selective targeting of prion-like forms of AβO, continues to support the development of PMN310 as a potentially impactful treatment for Alzheimer’s disease.” 

ProMIS now plans to initiate cell line development of humanized PMN310 at a specialized contract research organization (CRO). Cell line development is the first critical step in the highly regulated manufacture of biologic therapeutics, including mAbs. Following successful cell line development, final manufacturing process and scale up will take place at a specialized contract manufacturing organization (CMO).

Commenting on today’s announcement, Eugene Williams, ProMIS Executive Chairman, stated:

“We look forward to continued progress with our Alzheimer’s portfolio, targeting availability of clinical grade humanized PMN310 for evaluation in clinical trials planned to start in 2019. In addition, we are also initiating several comparative preclinical evaluations of our lead product cnadidate, PMN310, against other clinical-stage antibodies to demonstrate a potential best in class profile with respect to safety and efficacy in Alzheimer’s.”

 

About PMN310.

PMN310 was designated ProMIS’ first lead product candidate in January 2017, based on its ability to selectively bind prion-like forms of Amyloid beta oligomers (AβO), a recognized root cause of Alzheimer’s disease (AD). PMN310 displays an optimal binding profile, as it does not bind to amyloid beta monomer or plaque. Recent experimental and clinical evidence indicates that soluble toxic AβO, propagating in a prion-like manner, but not plaque or amyloid beta monomer, are actually the primary drivers of neurodegeneration and cognitive decline in AD patients. Accordingly, prior clinical trials of products targeting monomer, and/or plaque, have either failed (monomer targeting) or shown dose limiting side effects, in particular neurovascular edema, or brain swelling (plaque targeting).

Subsequent to PMN310, two other ProMIS monoclonal antibodies (mAbs) for AD, PMN350 and PMN330 each directed against different targets on toxic AβO, were designated lead development candidates this year, as they also display the optimal, selective target product profile in both in vitro and in vivo tests.

The ProMIS mAbs for AD have all been created in the mouse (murine mAbs). Hence, humanization of the original murine mAbs is required for use as human therapeutics so that the product is not rejected as foreign by the patient. Humanization (also called CDR-grafting) is now a well-established technique for reducing the immunogenicity (rejection potential) of therapeutic mAbs from non-human sources, such as the mouse. Humanization can lead to no change, an increase or decrease in binding affinity of the mAb on a case by case basis. In the case of PMN310, humanization has led to a ten-fold increase in the product candidate’s affinity (ability to bind and to stay bound to its target), thereby adding to its attractiveness as a lead product candidate for therapeutic development in AD.

Finally, ProMIS continues to focus on a precision medicine approach to AD. In this respect, the company is evaluating the binding profiles of each of the PMN series mAbs in several AD and non-AD brains, and comparing these to the binding profiles of other Ab antibodies either currently in development, or used in prior clinical trials. The company is also developing highly specific and sensitive assays to detect targets on toxic AβO in a cohort study of cerebrospinal fluid (CSF) from AD patients. The purpose of these two approaches is to assess population coverage as well as determine which of the PMN mAbs is the best therapeutic candidate for individual AD patients, thereby supporting a precision medicine approach to AD therapy.

 

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a Toronto Stock Exchange (TSX) listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts. The mission of ProMIS is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For further information please consult the Company's website at:

www.promisneurosciences.com

 

Follow us on Twitter
Like us on 
LinkedIn

 

For media inquiries, please contact:
RussoPartners/LLC
Scott.Santiamo@russopartnersllc.com
Tel. 718 344-5843

 

David Schull

RussoPartners/LLC

David.Schull@russopartnersllc.com

Tel. 858 717-2310

 

For Investor Relations please contact:

Alpine Equity Advisors

Nicholas Rigopulos, President

617-901-0785

nick@alpineequityadv.com

 

 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com

 

 

 

 

 

 

 

 

 

 



 

ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer’s Disease

 

TORONTO, Ontario and Cambridge, Massachusetts – Sept. 13, 2017 – ProMISNeurosciences, Inc., a company focused on discovery and development of precision treatmentsfor neurodegenerative diseases, today announced it has designated PMN330, a monoclonal antibody (mAb) targeting toxic prion-like forms of amyloid-beta oligomers (AβO), as its thirdlead product for development in Alzheimer’s disease (AD).

“We previously validated PMN310 and PMN350, our two lead products for development inAlzheimer’s disease based on their ability to selectively bind prion-like forms of AβO, inhibitingboth their propagation and neurotoxicity,” stated Dr. Neil Cashman, ProMIS’ Chief Scientific Officer. “We have now achieved a significant development milestone by demonstrating thatPMN330, directed against a different target on toxic AO, also displays an optimal target product profile in both in vitro and in vivo tests.” 

Injection of prion-like forms of AβO (also called toxic soluble oligomers) into the brains of mice causes a neurological deficit that can be assessed in a memory-behavior test called ‘novel object recognition’.  Normal mice exposed to an object remember the familiar object when re-exposed to it and spend more time exploring a newly introduced object. In contrast, AβO-injected mice lose the ability to discriminate between known and novel objects and spend equivalent amounts of time exploring both. Results obtained in this assay showed that administration of PMN330 to mice completely prevented the loss of short-term memory formation caused by toxic oligomers. Furthermore, the observed cognitive benefit of PMN330 was correlated with statistically significant preservation of two synaptic biomarkers (SNAP25, PSD95), indicative of neuroprotection, and reduction in a biomarker of neuroinflammation (TNFα) measured in hippocampal brain homogenates. This neuroprotective effect of PMN330 was investigated at a leading contract research organization specializing in neurodegenerative diseases. 

“These encouraging results underline the robust nature of our proprietary discovery engine,”commented Elliot Goldstein, MD, ProMIS’ President and CEO. “We now have three validateddevelopment candidates for Alzheimer’s selectively addressing a different target on toxic prion-like forms of AβO. The first of these, PMN310, is on track for initiation of clinical trials in 2019.”

 

About ProMIS Neurosciences, Inc. 

ProMIS Neurosciences is a Toronto Stock Exchange (TSX) listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts. The mission of ProMIS is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS. 

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target. 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

 

For further information please consult the Company's website at: 

www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn


RussoPartners/LLC
Scott.Santiamo@russopartnersllc.com
Tel. 718 344-5843

David Schull

RussoPartners/LLC

David.Schull@russopartnersllc.com

Tel. 858 717-2310

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com

 

 

 

 

 

 

 

 

 

 



 

ProMIS Neurosciences Completes Second Closing of Private Placement

TORONTO, ONTARIO – August 28, 2017 – ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX:PMN; OTCPK:ARFX.F; DB:23J) is pleased to announce that, further to its news releases dated July 20, 2017, August 2, 2017 and August 9, 2017, it has completed the final closing on a non-brokered private placement basis of its previously announced private placement (the “Offering”) of units of the Company for gross proceeds of $1,070,000.  In two closings, the Company has raised aggregate gross proceeds of approximately $4,800,000 under the Offering.  

Commenting on today’s announcement, Elliot Goldstein, M.D., ProMIS President and CEO stated, “We are very pleased to have closed our largest investment round to date, at a significant step up in value over previous rounds. This will allow us to continue our rapid rate of progress in building a portfolio of therapies in neurodegenerative diseases, including Alzheimer’s.” 

In the second closing, the Company issued 4,280,000 units at a price of $0.25 per unit. Each unit consisted of one common share of the Company and one-half of one share purchase warrant of the Company. Each warrant is exercisable to acquire one share for a period of 60 months at an exercise price of $0.30 per share, subject to acceleration. The expiry date of the warrants is subject to acceleration if following the four month anniversary of issuance, the volume weighted average trading price of the shares on the Toronto Stock Exchange exceeds $0.90 for ten consecutive trading days. At this time, the Company may accelerate the expiry date of the warrants by issuing a news release announcing the reduced warrant term whereupon the warrants will expire on the 30thcalendar day after the date of such news release. 

In connection with the Offering in Canada, certain finders received a cash commission and compensation warrants to purchase compensation shares for a period of 60 months following the date hereof at an exercise price of $0.285 per share (the “Compensation Options”).

Noble Capital Markets, Inc., which is acting as the exclusive placement agent for subscribers residing in the United States, received 7% cash commission of the gross proceeds of the Offering placed with U.S. subscribers (not including subscriptions received from insiders) and was issued Compensation Options to purchase up to 21,000 shares in respect of such U.S. subscribers. 

The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes. All securities issued in connection with the Offering are subject to a four-month hold period that expires on December 28, 2017.

One insider of the Company subscribed for 120,000 units, which constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The issuance to the insider is exempt from the formal valuation and the minority shareholder approval requirements of MI 61-101 as the fair market value of the units issued to or the consideration paid by such person did not exceed 25% of the Company’s market capitalization. 

This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements.

About ProMIS Neurosciences Inc.

ProMIS Neurosciences is a Toronto Stock Exchange (TSX) listed biotechnology company (trading symbol: PMN.TO), headquartered in Toronto, Ontario with offices in Cambridge, Massachusetts. The Company’s mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique “precision medicine” approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target. 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information, including the expected use of proceeds from the Offering and the expected amount and timing of the second closing. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company’s website at: 

www.promisneurosciences.com

 

Follow us on Twitter
Like us on LinkedIn


RussoPartners/LLC
Scott.Santiamo@russopartnersllc.com
Tel. 718 344-5843

 

David Schull

RussoPartners/LLC

David.Schull@russopartnersllc.com

Tel. 858 717-2310

 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com



 

 

ProMIS Neurosciences Announces Second Quarter 2017 Results 

TORONTO, ONTARIO and CAMBRIDGE, MA –August 11, 2017 – ProMIS Neurosciences, Inc. (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results for the three and six months ended June 30, 2017.

Commenting on the update, Elliot Goldstein, M.D., ProMIS President and CEO stated, “We are pleased with the substantial progress achieved at ProMIS. Our main focus now is to advance the development of our lead product candidates for Alzheimer’s disease, PMN310 and PMN350, with particular emphasis on the preclinical program to differentiate our leads compared to competitive antibody products in development. We remain confident that our monoclonal antibody programs focused on selectively targeting the toxic, prion-like forms of Amyloid betamay lead to best in class therapies and significant long-term value creation”. 

Recent Corporate Highlights

Financial Results

Results of Operations – Three months ended June 30, 2017 and 2016

The net loss for the three months ended June 30, 2017 was $1,903,396, compared to a net loss of $711,942 for the three months ended June 30, 2016.  The increased loss in the current period reflects the costs associated with operating the Company’s AD therapeutics program, supporting its patent portfolio, associated general corporate expenditures and higher stock-based compensation.   

Research and development expenses for the three months ended June 30, 2017 were $1,245,398 as compared to $315,027 in the three months ended June 30, 2016.  Costs are higher in the current period due to higher research program costs for the AD therapeutics program and higher stock-based compensation.  

General and administrative expenses for the three months ended June 30, 2017 were $655,556 as compared to $392,188 in the three months ended June 30, 2016.  The increased expenditures in the current period reflect higher investor relations expenses, higher salaries related to expansion of the senior management team, higher professional fees, and higher stock-based compensation.  

Results of Operations – Six months ended June 30, 2017 and 2016

The net loss for the six months ended June 30, 2017 was $3,275,599, compared to a net loss of $1,382,092 for the six months ended June 30, 2016.  The increased loss in the current period reflects the costs associated with operating the Company’s AD therapeutics program, supporting its patent portfolio, associated general corporate expenditures and higher stock-based compensation.   

Revenues for the six months ended June 30, 2017 and 2016 were nominal and relate to legacy technologies.  For the six months ended June 30, 2017, the Company recognized $658 in royalty revenue related to its preclinical AD diagnostic assay as compared to $2,486 for the six months ended June 30, 2016.  

Research and development expenses for the six months ended June 30, 2017 were $1,986,068 as compared to $676,511 in the six months ended June 30, 2016.  Costs are higher in the current period due to higher research program costs for the AD therapeutics program and higher stock-based compensation.  

General and administrative expenses for the six months ended June 30, 2017 were $1,285,348 as compared to $697,056 in the six months ended June 30, 2016.  The increased expenditures in the current period reflect higher investor relations expenses, higher salaries related to expansion of the senior management team, higher professional fees, and higher stock-based compensation.  

 

Outlook

The Company’s priorities for the next year are to identify and develop precision medicine therapeutics for AD and ALS. 

The Company’s plan is to further advance its AD portfolio, including the development of its lead products, PMN310 and PMN350, with a focus on competitive differentiation. Furthermore, the Company plans to continue on-going development of effective AD diagnostics for detection of toxic prion strains targeted by ProMIS antibody therapeutic candidates in either cerebrospinal fluid (CSF) or blood. Technology refinement and optimization are ongoing to create highly sensitive assays for this purpose.

The Company will continue to expand its intellectual property (IP) estate relating to novel epitope targets and antibodies targeting such epitopes on misfolded strains of Amyloid beta (Aβ)and Tau for AD and on misfolded strains of TDP43 for ALS and frontotemporal dementia. The Company’s complementary proprietary platform technologies, ProMISTM and Collective Coordinates, will be employed to identify and confirm such novel targets. 

Given the Company’s robust IP estate relating to misfolded SOD1 in ALS and the recently announced program to identify novel ALS therapeutic targets on toxic strains of the protein TDP43, ProMIS is seeking a collaborative development partnership in this field.

 

About ProMIS Neurosciences, Inc. 

ProMIS Neurosciences is a Toronto Stock Exchange (TSX) listed biotechnology company (trading symbol: PMN.TO), headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. The Company's mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer'sdisease and amyotrophic lateral sclerosis (ALS). The Company’s   proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets, known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The Company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. The Company owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS and currently has a preclinical monoclonal antibody therapeutic against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information, including about the timing and completion of the Offering, the receipt of TSX approval and the expected use of proceeds from the Offering. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For further information please consult the Company's website at: 

www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

For media inquiries, please contact:

Scott Santiamo
RussoPartners/LLC
Scott.Santiamo@russopartnersllc.com
Tel. 718 344-5843

David Schull

RussoPartners/LLC

David.Schull@russopartnersllc.com

Tel. 858 717-2310 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com

 

 

 

 

 



ProMIS Neurosciences Completes First Closing of Private Placement

/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

 

TORONTO, ONTARIO - August 9, 2017 - ProMIS Neurosciences Inc. ("ProMIS" or the "Company") (TSX:PMN; OTCPK:ARFX.F; DB:23J) is pleased to announce that, further to its news releases dated July 20, 2017 and August 2, 2017, it has completed the first closing of its previously announced $6 million private placement (the "Offering") of units of the Company for gross proceeds of approximately $3.72 million. The balance of the $6 million Offering is expected to close on or about August 23, 2017.

In the first closing, the Company issued 14,884,306 units at a price of $0.25 per unit. Each unit consisted of one common share of the Company and one-half of one share purchase warrant of the Company. Each warrant is exercisable to acquire one share at an exercise price of $0.30 per common share for a period of 60 months, subject to acceleration. The expiry date of the warrants is subject to acceleration such that if following the four month anniversary of issuance, the volume weighted average trading price of the shares on the Toronto Stock Exchange exceeds $0.90 for ten consecutive trading days, at which time the Company may accelerate the expiry date of the warrants by issuing a press release announcing the reduced warrant term whereupon the warrants will expire on the 30th calendar day after the date of such press release.

In connection with the Offering in Canada, Mackie Research Capital Corporation received a cash commission equal to 7% of the gross proceeds of the Offering placed in Canada, not including subscriptions received from insiders and certain finders, and 2% of the aggregate gross proceeds of the Offering on subscriptions received from certain finders. As additional compensation, the Company issued to Mackie compensation options (the "Compensation Options") to purchase up to 811,480 shares for a period of 60 months following the date of issuance at an exercise price of $0.285 per share.

Noble Capital Markets, Inc., which is acting as the exclusive placement agent for subscribers residing in the United States, received a cash commission equal to 7% of the gross proceeds of the Offering placed with US subscribers (not including subscriptions received from insiders) and was issued Compensation Options to purchase up to 199,330 shares in respect of such US subscribers.

The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes. All securities issued in connection with the first tranche of the Offering are subject to a four month hold period that expires on December 9, 2017.

Four insiders of the Company subscribed for 372,724 units, which constitutes a "related party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The issuances to the insiders are exempt from the formal valuation and the minority shareholder approval requirements of MI 61-101 as the fair market value of the units issued to or the consideration paid by such persons did not exceed 25% of the Company's market capitalization.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About ProMIS Neurosciences Inc.

ProMIS Neurosciences is a Toronto Stock Exchange (TSX) listed biotechnology company (trading symbol: PMN.TO), headquartered in Toronto, Ontario with offices in Cambridge, Massachusetts. The Company's mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and amyotrophic lateral sclerosis (ALS). ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform-ProMIS(TM) and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information, including the expected use of proceeds from the Offering and the expected amount and timing of the second closing. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For media inquiries, please contact:

Scott Santiamo 
RussoPartners/LLC
Scott.Santiamo@russopartnersllc.com,
Tel.718 344-5843

 

David Schull
RussoPartners/LLC
David.Schull@russopartnersllc.com
Tel. 858 717-2310

 

Dr. Elliot Goldstein
President and Chief Executive Officer
ProMIS Neurosciences Inc.
Tel. 415 341-5783
Elliot.goldstein@promisneurosciences.com



 

 

 

 

ProMIS Neurosciences Increases Size of Private Placement to $6 Million

 

/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

TORONTO, ONTARIO – August 2, 2017 – ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX:PMN; OTCPK:ARFX.F; DB:23J) today announced that it has increased the offering size of its previously announced financing to $6 million. Mackie Research Capital Corporation (the “Agent”) will continue to act as lead agent for the Offering whereby the Company will offer, on a private placement basis, up to 24,000,000 units (the “Units”) at a price of $0.25 per Unit (the “Offering Price”) for proceeds of up to $6,000,000 (the “Offering”). Noble Capital Markets, Inc. (“Noble”) will continue to act as the exclusive placement agent for subscribers residing in the United States.

Each Unit will consist of one common share of the Company (each a “Share”) and one-half of one share purchase warrant of the Company (each whole share purchase warrant, a “Warrant”). The term of the Warrant has been increased from a period of 36 months following the Closing Date (as defined below) to a period of 60 months following the Closing Date. Each Warrant will entitle the holder thereof to purchase one Share at an exercise price of $ 0.30 at any time up to 60 months following the Closing Date. The expiry date of the Warrants is subject to acceleration such that if following the four monthanniversary of the Closing Date, the volume weighted average trading price of the Shares on the Toronto Stock Exchange (TSX) exceeds $0.90 for ten consecutive trading days, the Company may accelerate the expiry date of the Warrants by issuing a press release announcing the reduced warrant term whereupon the Warrants will expire on the 30th calendar day after the date of such press release. 

Mackie Research Capital Corporation (the “Agent”) will continue to receive an option to offer up to that number of additional Units as is equal to 15% of the number of Units to be sold in its portion of the Offering pursuant to the engagement letter dated July 14, 2017, on the same terms and conditions as the Offering, increasing the size of the Offering up to a maximum of 25,800,000 Units and up to maximum gross proceeds of $6,450,000.

Net proceeds from the Offering are intended to be used for working capital and general corporate purposes.

On closing of the Offering, the Company will pay to the Agent a cash commission (the “Agent’s Fee”) equal to 7% of the gross proceeds of the Offering placed by the Agent, in cash, and will issue such number of broker warrants (the “Broker Warrants”) as is equal to 7% of the number of Units placed by the Agent. Each Broker Warrant will be exercisable to acquire one Share at the Offering Price for a period of 60 months from the Closing Date. For all Units purchased by US investors, Noble will be entitled to 7% Agent's Fee and 7% Broker Warrants.

 Closing of the Offering, which is subject to customary conditions, including TSX approval, is expected to occur on or about August 9, 2017 (the “Closing Date”). The Offering will be offered to qualified investors in the provinces of Alberta, British Columbia, Ontario and Quebec, and otherwise in those jurisdictions where the Offering can lawfully be made including the United States under applicable private placement exemptions. 

 This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. 

 

About ProMIS Neurosciences Inc.

ProMIS Neurosciences is a Toronto Stock Exchange (TSX) listed biotechnology company (trading symbol: PMN.TO), headquartered in Toronto, Ontario with offices in Cambridge, Massachusetts. The Company’s mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and amyotrophic lateral sclerosis (ALS). ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target. 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information, including about the timing and completion of the Offering, the receipt of TSX approval and the expected use of proceeds from the Offering. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For media inquiries, please contact: 

Scott Santiamo 

RussoPartners/LLC 

Scott.Santiamo@russopartnersllc.com

Tel.718 344-5843

David Schull

RussoPartners/LLC

David.Schull@russopartnersllc.com

Tel. 858 717-2310

Dr. Elliot Goldstein

President and Chief Executive Officer

ProMIS Neurosciences Inc.

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com

LEGAL_27587184.1



 

 

ProMIS Neurosciences Announces Results of AnnualMeeting of Shareholders

 

ProMIS’ shareholders show overwhelming support for allresolutions

TORONTO, ONTARIO and CAMBRIDGE, MA, July 31, 2017 - ProMIS Neurosciences, Inc. (the “Company”), a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced thevoting results of the Company’s annual meeting of shareholders held on June 28, 2017 in Toronto (the “Meeting”).

The Company is pleased to announce that all of the resolutions announced in the Management Proxy Circular dated May 18, 2017 and placed before the Meeting were approved by the shareholders. The total number of common shares represented by shareholders present in person or by proxy at the meeting was 66,942,577, representing 33.4% of the Company's outstanding common shares. A total of 56,195,054 common shares were represented by proxy and 10,747,523 common shares were represented by shareholders present in person

In particular, the following are the voting results for the 56,195,054 common shares that were voted by proxy.

 

  

DIRECTOR

FOR

WITHHELD

NOT VOTED

Neil Cashman

45,657,145

2,925

10,534,984

Dr. Elliot Goldstein

45,657,170

2,900

10,534,984

Patrick D. Kirwin

45,647,145

12,925

10,534,984

Johannes Roth

43,376,550

2,283,520

10,534,984

Eugene Williams

45,657,145

2,925

10,534,984

William Wyman

44,326,550

1,333,520

10,534,984

Dr. Richard J. Gregory

45,607,170

52,900

10,534,984

Anthony Giovinazzo

45,647,145

12,925

10,534,984

 

Please refer to the Company’s Management Proxy Circular available on SEDAR at

www.sedar.com for more details on the matters discussed at theMeeting.

About ProMIS Neurosciences Inc.

 ProMIS Neurosciences is a Toronto Stock Exchange (TSX) listed biotechnology company (trading symbol: PMN.TO), headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. The Company's mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The Company’s   proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets, known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The Company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. The Company owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS and currently has a preclinical monoclonal antibody therapeutic against this target.

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information, including about the timing and completion of the Offering, the receipt of TSX approval and the expected use of proceeds from the Offering. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company's website at: 

www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

For media inquiries, please contact:

Scott Santiamo
RussoPartners/LLC
Scott.Santiamo@russopartnersllc.com
Tel. 718 344-5843

David Schull

RussoPartners/LLC

David.Schull@russopartnersllc.com

Tel. 858 717-2310

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com

 



ProMIS Neurosciences Announces CDN$3 Million Best-Efforts Private Placement

 

/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

TORONTO, ON – July 20, 2017 – ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX:PMN; OTCPK:ARFX.F; DB:23J) today announced that it has entered into an agreement with Mackie Research Capital Corporation (the “Agent”) pursuant to which the Company will offer, on a private placement basis, up to 12,000,000 units (the “Units”) at a price of $0.25 per Unit (the “Offering Price”) for proceeds of up to $3,000,000 (the “Offering”). Noble Capital Markets, Inc. (“Noble”) has been engaged to act as the exclusive placement agent for subscribers residing in the United States.

Each Unit will consist of one common share of the Company (each a “Share”) and one-half of one share purchase warrant of the Company (each whole share purchase warrant, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Share at an exercise price of $ 0.30 at any time up to 36 months following the Closing Date (as defined below). The expiry date of the Warrants is subject to acceleration such that if following the four month anniversary of the Closing Date, the volume weighted average trading price of the Shares on the Toronto Stock Exchange exceeds $0.90 for ten consecutive trading days, at which time the Company may accelerate the expiry date of the Warrants by issuing a press release announcing the reduced warrant term whereupon the Warrants will expire on the 30th calendar day after the date of such press release.

The Company has granted the Agent an option to offer up to that number of additional Units as is equal to 15% of the number of Units to be sold in the Offering, on the same terms and conditions as the Offering, increasing the size of the Offering up to a maximum of 13,800,000 Units and up to a maximum gross proceeds of $3,450,000.

Net proceeds from the Offering are intended to be used for working capital and general corporate purposes.

On closing of the Offering, the Company will pay to the Agent a cash commission (the “Agent’s Fee”) equal to 7% of the gross proceeds of the Offering placed by the Agent, in cash, and will issue such number of broker warrants (the “Broker Warrants”) as is equal to 7% of the number of Units placed by the Agent. Each Broker Warrant is exercisable to acquire one Share at the Offering Price for a period of 36 months from the Closing Date. For all Units purchased by US investors, Noble will be entitled to 7% Agent's Fee and 7% Broker Warrants.

Closing of the Offering, which is subject to customary conditions, including TSX approval, is expected to occur on or about August 3, 2017 (the “Closing Date”). The Offering will be offered to qualified investors in the provinces of Alberta, British Columbia and Ontario, and otherwise in those jurisdictions where the Offering can lawfully be made including the United States under applicable private placement exemptions.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

 

 

About ProMIS Neurosciences Inc.

ProMIS Neurosciences is a TSX listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario with offices in Cambridge, Massachusetts. The Company’s mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS. ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information, including about the timing and completion of the Offering, the receipt of TSX approval and the expected use of proceeds from the Offering. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For media inquiries, please contact:

Scott Santiamo

RussoPartners/LLC

Scott.Santiamo@russopartnersllc.com,

Tel.718 344-5843

 

David Schull

RussoPartners/LLC

David.Schull@russopartnersllc.com

Tel. 858 717-2310

 

Dr. Elliot Goldstein

President and Chief Executive Officer

ProMIS Neurosciences Inc.

 

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com



AAIC Whitepaper July 19 2017

 

STATE OF THE ART AT AAIC 2017

This year’s Alzheimer’s Association International Conference (AAIC) is the largest yet with 5,600 experts from around the world representing medical institutions, academia and industry.   It is striking that the field now appears to have reached a consensus on the central role of toxic amyloid-beta oligomers (AβO) in the pathogenesis of Alzheimer’s disease (AD).  In the July 17 plenary session, Dr. Dennis Selkoe (Brigham and Women’s Hospital, Boston, MA) presenting to a packed audience, described AD as a condition initiated by a chronic imbalance between production and clearance of Aβ peptide which favors the formation of toxic oligomers (soluble aggregates of Aβ peptide monomers).  He outlined evidence showing that AβO present at high levels in AD brains are highly neurotoxic causing synaptic damage and memory impairment when injected into healthy animals. In contrast, Aβ monomers and plaque are not toxic to cultures of neurons or when injected into the brain of mice.  His data show that plaque may actually be protective by sequestering toxic oligomers.  The weight of this evidence indicates that successful therapies will need to specifically target toxic AβO as stated by Dr. Eliezer Masliah (National Institute on Aging) in his plenary lecture at the America Academy of Neurology (AAN) annual meeting earlier this year.

Similarly, Dr. Mathias Jucker (University of Tubingen, Germany), in his July 18 symposium presentation entitled “The Prion-Like Properties of Amyloid-β”, outlined evidence showing that soluble AβO (Aβ seeds) propagate like prions throughout the brain when injected into mice and can be transmitted from mouse to mouse.  Examination of human AD brains showed that different strains could be found in different AD subgroups (e.g. familial vs sporadic AD).  These findings not only support targeting of toxic AβO to get at the root cause of AD but also advocate for a precision medicine approach tailored to the patient.

ProMIS’ platform presentation of July 17 entitled “Targeting of Toxic Amyloid-Beta Oligomer Species by Monoclonal Antibody PMN310: Precision Drug Design for Alzheimer’s Disease” was in complete alignment with the most current understanding of the pathogenesis of AD and addresses the issues that were raised regarding AβO targeting and patient heterogeneity.  Specificity for toxic AβO is essential for a therapeutic antibody as binding to the much more abundant Aβ monomers is a distraction from the real target and is expected to reduce efficacy, while binding to plaque has been associated with an increased incidence of adverse brain edema (ARIA-E) and micro-hemorrhages (ARIA-H).   We described how the use of proprietary computer modeling algorithms allowed us to identify five different epitopes likely to be exposed in the context of misfolded toxic oligomers but not in monomers or plaque.  These conformational epitopes were used for immunization to generate monoclonal antibodies that underwent a screening process to select the best-performing candidates.  First, surface plasmon resonance (SPR) was used to select antibodies that showed preferential binding to conformational vs linear epitope, oligomers vs monomers and binding to native oligomers in the cerebrospinal fluid (CSF) and soluble brain homogenates from AD patients vs controls.  The lack of plaque binding was confirmed on sections of plaque-containing AD brains.  Antibodies with the desired oligomer-selective binding profile were then tested in vitro for their ability to inhibit oligomer propagation and to protect cultures of mouse neurons from oligomer toxicity.  Finally, antibodies underwent in vivo testing in an acute toxicity assay where the brains of mice were injected with toxic AβO with or without test antibody.  The ability of the antibodies to prevent the AβO-induced loss of short-term memory formation in these mice was measured seven days later in a novel object recognition assay. The brains were then collected and hippocampal homogenates analyzed to assess the benefit of antibody treatment on markers of inflammation (TNF-α) and synaptic damage (SNAP25, PSD-95).  Using this screening process, antibody candidates with the desired binding profile were identified for all five epitopes and additional in vivo assays led to the selection of PMN310 and PMN350 as lead candidates against two of the epitopes.  Our assessment of antibodies against the other three epitopes continues.

Importantly, the observed detection by ProMIS antibodies of target epitopes in CSF offers the possibility of a precision medicine approach tailored to the patient which is more likely to be successful than a “one size fits all” approach.

Expanding on the role of AβO in AD pathology, evidence was also presented by Dr. Selkoe that AβO can trigger Tau phosphorylation which precedes the conversion to a pathogenic form of Tau.  The prion-like propagation of misfolded, aggregated Tau was extensively described in symposium presentations by Drs. Marc Diamond (University of Texas Southwestern Medical Center) and Florence Clavaguera (Institute of Pathology, Basel, Switzerland).  A similar prion-like transmission of aggregated α-synuclein in Parkinson’s disease was described by Dr. Jeffrey Kordower (Rush University, Chicago).  Propagation of toxic misfolded proteins, now recognized as a general mechanism underlying several neurodegenerative diseases, is being addressed with the ProMIS approach to generate antibodies against disease-specific epitopes.  Programs are ongoing for Aβ (AD), SOD1 (ALS), TDP43 (ALS, frontotemporal dementia), Tau (AD, tauopathies) and α-synuclein (Parkinson’s disease).   



 

 

ProMIS Neurosciences Presents at AAIC 2017 Data from Alzheimer’s Disease Program

Company Focused on Development of Antibodies that Selectively Target Toxic, Prion-Like Forms of Amyloid beta

ProMIS Issues White Paper from AAIC Presentations Outlining Role of Toxic Misfolded Forms of Amyloid beta and Tau in Alzheimer’s Disease 

 

TORONTO, Ontario and CAMBRIDGE, Massachusetts – July 19, 2017 – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the presentation of its precision design approach and preclinical data for its lead product candidates, at the Alzheimer’s Association International Conference (AAIC) being held in London from July 16-20.

Below are key highlights of the presentation by Kaplan et al., entitled Targeting of toxic amyloid-beta oligomer species by monoclonal antibody PMN310: Precision drug design for Alzheimer’s disease:

 

 

Commenting on the ProMIS podium presentation at AAIC, Eugene Williams, ProMIS Executive Chairman stated: “We continue to make significant progress with our Alzheimer’s program, selectively targeting toxic amyloid beta oligomers, widely recognized at the conference to be a root cause of Alzheimer’s. The unique characteristics of our lead products in development, PMN310 and PMN350, distinguishes them from other antibodies targeting amyloid beta currently undergoing clinical trials and are designed to address observed issues of safety and efficacy”. 

 

 

Several presentations at the AAIC meeting by other specialist groups in the field also underlined the importance of selectively targeting and neutralizing toxic AbO for effective treatment of Alzheimer’s.

A white paper, summarizing these reports, as well as offering more detailed information on the ProMIS AAIC presentation is available on the ProMIS Neurosciences website at:  http://bit.ly/2u4yp5t

  

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a TSX listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts. The mission of ProMIS is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

For further information please consult the Company's website at:

 

www.promisneurosciences.com

 

Follow us on Twitter
Like us on LinkedIn 

For media inquiries, please contact:

 

Scott Santiamo
RussoPartners/LLC
Scott.Santiamo@russopartnersllc.com
Tel. 718 344-5843

David Schull

 

RussoPartners/LLC

 

David.Schull@russopartnersllc.com

 

Tel. 858 717-2310

cbealamaro@streetwisereports.com

Dr. Elliot Goldstein

 

President and Chief Executive Officer, ProMIS Neurosciences Inc.

 

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com

   

 

 





ProMIS Neurosciences Provides Second Quarter Update for 2017 and Outlook for Near-Term Value Creation

 

Updated corporate overview available on ProMIS website

 

TORONTO, Ontario and CAMBRIDGE, Massachusetts – July 10, 2017 – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today provided a corporate update for the second quarter of 2017, including key accomplishments, a status update on ongoing programs, and the Company’s outlook for near-term value creation.

A narrated corporate overview of second quarter 2017 progress and outlook for the future is available on the ProMIS Neurosciences website at: http://bit.ly/2tRLGAI.

Key accomplishments in the second quarter of 2017 and near-term value drivers include:

 

 Commenting on the update, ProMIS Executive Chairman Eugene Williams stated: “We are pleased with the continued progress at ProMIS and remain confident that our monoclonal antibody programs focused on selectively targeting the toxic, prion-like forms of Amyloid beta may lead to best in class therapies and significant long-term value creation”.  

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a TSX listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario with offices in Cambridge, Massachusetts. The Company’s mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.  

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company's website at:
www.promisneurosciences.com
 
Follow us on Twitter
Like us on LinkedIn
 
For media inquiries, please contact:
 
Scott Santiamo
RussoPartners/LLC
Scott.Santiamo@russopartnersllc.com
Tel. 718 344-5843
 
David Schull
 
RussoPartners/LLC
 
David.Schull@russopartnersllc.com
 
Tel. 858 717-2310
 
cbealamaro@streetwisereports.com
  
Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
 
Tel. 415 341-5783
 
Elliot.goldstein@promisneurosciences.com


 

ProMISTM Neurosciences’ Sponsored Research Agreement with University of British Columbia Receives Matching Grant from Canadian Institutes of Health Research

 

TORONTO, Ontario and CAMBRIDGE, Massachusetts – July 6, 2017 – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that the Company’s sponsored research agreement with the University of British Columbia (UBC) has received a matching Industry Partnered Grant from the Canadian Institutes of Health Research (CIHR).

The peer-reviewed matching grant of $262,500 from CIHR supports the multi-year, Company-sponsored agreement, which is focused on furthering the evaluation and characterization of antibodies specifically targeting toxic amyloid beta (Abeta) oligomers under development by ProMIS Neurosciences, including lead development products PMN310 and PMN350.

Commenting on today’s announcement, Dr. Neil Cashman, ProMIS Chief Scientific Officer and   Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases at UBC, stated:

“The research resulting from the ProMIS sponsored research agreement and related CIHR grant will provide a strong preclinical foundation to support the rapid advancement of our clinical candidates for oligomer-specific immunotherapy of Alzheimer's disease.”

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a TSX listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario with offices in Cambridge, Massachusetts. The Company’s mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

 

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company's website at:

 

www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

For media inquiries, please contact:

 

Scott Santiamo
RussoPartners/LLC
Scott.Santiamo@russopartnersllc.com
Tel. 718 344-5843

David Schull

 

RussoPartners/LLC

 

David.Schull@russopartnersllc.com

 

Tel. 858 717-2310

cbealamaro@streetwisereports.com

Dr. Elliot Goldstein

 

President and Chief Executive Officer, ProMIS Neurosciences Inc.

 

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com

 

 

 

 

 



ProMIS Neurosciences to Present Preclinical Data from Alzheimer's Disease Program at AAIC 2017

Chief Development Officer Dr. Johanne Kaplan to chair session

ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC): 16-20 JULY, 2017 LONDON, ENGLAND

TORONTO, Ontario and CAMBRIDGE, Massachusetts - July 5, 2017- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the Company will present preclinical data for its lead product candidate, PMN310, at the Alzheimer's Association International Conference (AAIC) to be held in London on July 16-20.

Johanne Kaplan, Ph.D., ProMIS Chief Development Officer, will present the data and chair the associated session, entitled Preclinical: Basic Therapeutics - Targeting Amyloid or Tau.

The presentation by Kaplan (et al.), entitled Targeting of toxic amyloid-beta oligomer species by monoclonal antibody PMN310:  Precision drug design for Alzheimer's disease describes the use of ProMIS' proprietary discovery engine for the identification and generation of monoclonal antibodies against specific targets on toxic forms of amyloid beta (A-beta), a recognized root cause of Alzheimer's.

Commenting on the presentation, Dr. Kaplan stated, "Antibody PMN310 was selected as our lead product for development on the basis of its ability to selectively target and neutralize toxic A-beta oligomers with no significant off-target binding to A-beta monomers or fibrils. These characteristics distinguish PMN310 from other A-beta antibodies currently undergoing clinical trials, and are designed to achieve optimal efficacy and safety".

ProMIS is very pleased to contribute to this year's AAIC, the world's largest forum where international investigators, clinicians and care providers gather to share the latest study results, theories and discoveries that will help bring the world closer to breakthroughs in dementia science.

The session and presentation details are as follows:

Session: Preclinical: Basic Therapeutics - Targeting Amyloid or Tau

Presentation: Targeting of toxic amyloid-beta oligomer species by monoclonal antibody PMN310:  Precision drug design for Alzheimer's disease

Date/Time of session: 4:15-5:45 PM, July 17, 2017

Location: ExCel, London, Royal Victoria Dock

 

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a TSX listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts. The mission of ProMIS is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.

ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform-ProMIS(TM) and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company's website at:

www.promisneurosciences.com

For media inquiries, please contact:

Scott Santiamo
RussoPartners/LLC
Scott.Santiamo@russopartnersllc.com
Tel. 718 344-5843

David Schull
RussoPartners/LLC
David.Schull@russopartnersllc.com
Tel. 858 717-2310

cbealamaro@streetwisereports.com

Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
Elliot.goldstein@promisneurosciences.com



ProMIS Neurosciences, Inc.

 

NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE

 

ProMIS Neurosciences Identifies Novel Therapeutic Epitope Target for ALS and Dementia 

                              

Company files United States patent application for novel epitope target identified on misfolded forms of the protein TDP43

 

TORONTO, Ontario and CAMBRIDGE, Massachusetts – May 31, 2017 – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the identification of a novel therapeutic epitope target on misfolded forms of TDP43, implicated in the development and progression of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The Company filed a provisional patent application for this target with the United States Patent Office on May 30, 2017.

 

Commenting on today’s announcement, Dr. Neil Cashman, ProMIS Chief Scientific Officer, stated: “Using our proprietary discovery engine, scientists at UBC and ProMIS identified both the sequence and conformational shape of this novel epitope target on misfolded TDP43 that plays a key role in ALS and frontotemporal dementia.”

 

TDP43 is present in every cell, and plays a critical role in the response of cells to oxidative stress. However, in ALS, FTD and other neurodegenerative diseases, TDP43 can lose its normal function, forming intracellular aggregates of misfolded TDP43 that disrupt cellular energy generation and normal protein degradation. 

 

“Our goal is to selectively target misfolded TDP43 without disrupting the critical role that normally-folded TDP43 plays in cell biology,” stated Dr. Elliot Goldstein, ProMIS President and CEO. “We plan to create and validate monoclonal antibodies against misfolded TDP43 to select optimal therapeutic candidates for advancement into the clinic.” 

 

Pursuant to its expanded license agreement with the University of British Columbia, ProMIS holds exclusive, worldwide license to this novel therapeutic target.

 

About ProMIS Neurosciences, Inc.

 

ProMIS Neurosciences is a TSX listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts. The mission of ProMIS is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

 

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For further information please consult the Company's website at:

www.promisneurosciences.com

 

Follow us on Twitter
Like us on LinkedIn

 

For media inquiries, please contact:

 

Scott Santiamo
RussoPartners/LLC
Scott.Santiamo@russopartnersllc.com
Tel. 718 344-5843

 

David Schull

RussoPartners/LLC

David.Schull@russopartnersllc.com

Tel. 858 717-2310

 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com

 

 



ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to present at Prion 2017 International Conference

TORONTO and CAMBRIDGE, Mass., May 25, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN), a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, announced that Neil Cashman, MD,  Chief Scientific Officer and Co-Founder will present today at PRION 2017, the International Conference Deciphering Neurodegenerative Disorders in Edinburgh, Scotland.

Dr. Cashman's presentation, entitled Epitope Identification of Toxic Propagating Strains of Aß Oligomers, describes the use of ProMIS' proprietary discovery engine to identify targets (epitopes) on toxic prion-like forms of Amyloid beta oligomers (AßO), considered a root cause of Alzheimer's disease.

Commenting on the presentation, Dr. Cashman stated, "we have been able to raise antibodies against these epitopes that selectively bind the toxic prion-like forms of Amyloid beta and block their neurotoxicity and propagation. To date, two of these antibodies - PMN310 and PMN350 - each selectively addressing a different target epitope -  have been designated as our lead products for development in Alzheimer's disease."

Organizers of the conference anticipate participation of more than 400 academics, strategists, innovators, policy makers and researchers from public and private sector across the international field of Prion research. The 14th annual conference will gather attendees to discuss the latest research being carried out in prion diseases and the broader field of neurodegenerative diseases and to examine the commonalities and differences between these devastating diseases.

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a TSX listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts. The mission of ProMIS is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.

ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform-ProMIS(TM) and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company's website at: 
www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

For media inquiries, please contact:

Scott Santiamo
RussoPartners/LLC
Scott.Santiamo@russopartnersllc.com
Tel. 718 344-5843

David Schull
RussoPartners/LLC
David.Schull@russopartnersllc.com
Tel. 858 717-2310

Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
Elliot.goldstein@promisneurosciences.com



ProMIS Neurosciences, Inc.

 

NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE

 

ProMIS Neurosciences declares PMN350 its second lead product for development in Alzheimer’s disease

 

TORONTO, Ontario and Cambridge, Massachusetts – May 24, 2017 – ProMIS Neurosciences, a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced that PMN350, a monoclonal antibody (mAb) targeting toxic prion-like forms of amyloid-beta oligomers (AβO), has been designated its second lead product for development in Alzheimer’s disease (AD).

 

“We previously demonstrated that PMN310, our first lead product for development in Alzheimer’s disease, presents the optimal target profile of selectively binding prion-like forms of AβO, inhibiting both their propagation and neurotoxicity,” stated Dr. Neil Cashman, ProMIS Chief Scientific Officer. “We have now achieved a significant development milestone by demonstrating that PMN350, our second AD lead product directed against a different target on toxic AbO, also displays the optimal target product profile in both in vitro and in vivo tests.”

 

The neuroprotective effect of PMN350 was investigated at SynAging, SAS, a leading contract research organization (CRO) specializing in neurodegenerative diseases.  

Injection of prion-like forms of AβO (also called toxic soluble oligomers) into the brains of mice causes a neurological deficit that can be assessed in a memory-behavior test called novel object recognition.  Normal mice exposed to an object remember the familiar object when re-exposed to it and spend more time exploring a newly introduced object. In contrast, AβO-injected mice lose the ability to discriminate between known and novel objects and spend equivalent amounts of time exploring both. Results obtained in this assay showed that administration of PMN350 to mice completely prevented the loss of short-term memory formation caused by toxic oligomers. Furthermore, the observed cognitive benefit of PMN350 was correlated with a statistically significant improvement of two synaptic biomarkers (SNAP25, PSD95) and a biomarker of inflammation (TNFα) measured in hippocampal brain homogenates.

 

“We are pleased that our propriety discovery engine has produced a second lead product with the potential to treat Alzheimer’s,” commented Dr. Elliot Goldstein, ProMIS President and CEO. “With two lead development products, PMN310 and PMN350 each selectively addressing a different target (epitope) on toxic prion-like forms of AβO, we look forward to initial evaluation of their relative prevalence in cerebrospinal fluid samples from AD patients, thereby paving the way for a precision medicine approach to this devastating disease.

 

 

 

 

About SynAging, SAS

 

SynAging focuses on disease-inducing protein aggregates which are involved in the earliest stages of proteopathic neurodegenerative diseases, like Alzheimer’s and Parkinson’s. Proteopathic diseases are those in which certain proteins become structurally abnormal, and thereby disrupt the function of cells, tissues and organs of the body. SynAging is a contract research organization based in Nancy, France, providing highly reproducible drug testing services, employing proprietary protein aggregates to initiate symptoms of neurodegenerative diseases in vitro and in vivo.

 

For further information please consult the SynAging website at:

www.synaging.com

 

 

About ProMIS Neurosciences, Inc.

 

ProMIS Neurosciences is a TSX listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts. The mission of ProMIS is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

 

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For further information please consult the Company's website at:

www.promisneurosciences.com

 

Follow us on Twitter
Like us on LinkedIn

 

For media inquiries, please contact:

 

Scott Santiamo
RussoPartners/LLC
Scott.Santiamo@russopartnersllc.com
Office: (212) 845-4235
Mobile: (718) 344-5843

 

cbealamaro@streetwisereports.com

 

or contact

 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com

 

 

 

 



May 24, 2017 7:30 AM

ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer's Disease

TSX: PMN

TORONTO and CAMBRIDGE, MA, May 24, 2017 /CNW/ - ProMIS Neurosciences, a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced that it has designated PMN350 - a monoclonal antibody (mAb) targeting toxic prion-like forms of amyloid-beta oligomers (AβO) - as the Company's second lead product for Alzheimer's disease (AD).

ProMIS Neurosciences Inc. (CNW Group/ProMIS Neurosciences Inc.)

"We previously demonstrated that PMN310, our first lead product for development in Alzheimer's disease, presents the optimal target profile of selectively binding prion-like forms of AβO, inhibiting both their propagation and neurotoxicity," stated Dr. Neil Cashman, ProMIS Chief Scientific Officer. "We have now achieved a significant development milestone by demonstrating that PMN350, our second AD lead product directed against a different target on toxic AbO, also displays the optimal target product profile in both in vitro and in vivo tests."

The neuroprotective effect of PMN350 was investigated at SynAging, SAS, a leading contract research organization (CRO) specializing in neurodegenerative diseases. Injection of prion-like forms of AβO (also called toxic soluble oligomers) into the brains of mice causes a neurological deficit that can be assessed in a memory-behavior test called novel object recognition.  Normal mice exposed to an object remember the familiar object when re-exposed to it and spend more time exploring a newly introduced object. In contrast, AβO-injected mice lose the ability to discriminate between known and novel objects and spend equivalent amounts of time exploring both. Results obtained in this assay showed that administration of PMN350 to mice completely prevented the cognitive impairment caused by toxic oligomers. Furthermore, the observed cognitive benefit of PMN350 was correlated with a statistically significant improvement of two synaptic biomarkers (SNAP25, PSD95) and a biomarker of inflammation (TNFα) measured in hippocampal brain homogenates.

"We are pleased that our propriety discovery engine has produced a second lead product with the potential to treat Alzheimer's," commented Dr. Elliot Goldstein, ProMIS President and CEO. "With two lead development products, PMN310 and PMN350, each selectively addressing a different target (epitope) on toxic prion-like forms of amyloid-beta oligomers, we look forward to initial evaluation of their relative prevalence in cerebrospinal fluid samples from Alzheimer's patients, thereby paving the way for a precision medicine approach to this devastating disease."

About SynAging, SAS

SynAging focuses on disease-inducing protein aggregates which are involved in the earliest stages of proteopathic neurodegenerative diseases, like Alzheimer's and Parkinson's. Proteopathic diseases are those in which certain proteins become structurally abnormal, and thereby disrupt the function of cells, tissues and organs of the body. SynAging is a contract research organization based in Nancy, France, providing highly reproducible drug testing services, employing proprietary protein aggregates to initiate symptoms of neurodegenerative diseases in vitro and in vivo.

For further information please consult the SynAging website at:
www.synaging.com

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a TSX listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts. The mission of ProMIS is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.

ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company's website at:
www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

SOURCE ProMIS Neurosciences Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/May2017/24/c3869.html

For media inquiries, please contact: Scott Santiamo, RussoPartners/LLC, Scott.Santiamo@russopartnersllc.com, Office: (212) 845-4235, Mobile: (718) 344-5843; cbealamaro@streetwisereports.com; or contact Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel. 415 341-5783, Elliot.goldstein@promisneurosciences.comCopyright CNW Group 2017



ProMISTM Neurosciences, Inc.

 

NEWS RELEASE TSX: PMN

FOR IMMEDIATE RELEASE

 

ProMIS Neurosciences Announces Q1 2017 Annual Results

 TORONTO, Ontario –May 9, 2017 – ProMIS Neurosciences, Inc. (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results for the three months ended March 31, 2017.

 

"We continue to make significant progress on our Alzheimer’s disease (AD) program” said Dr. Elliot Goldstein, ProMIS CEO. "Our priorities are to further advance development of ProMIS’ lead product, PMN 310, with a goal of IND submission by the end of 2018, to complete a cohort study to determine the prevalence of different prion strains of Amyloid beta in AD, and to initiate development of effective AD diagnostics for detection of toxic prion strains in cerebrospinal fluid (CSF) or blood.”

 

ProMIS also announced continued work on two new drug development programs to identify novel therapeutic targets on Tau for AD, and TDP43 for Amyotrophic Lateral Sclerosis (ALS) and frontotemporal dementia (FTD), representing additional opportunities to apply its complementary platform technologies.

 

Recent Corporate Highlights

·      PMN 310, declared lead development product, on track for IND submission at the end of 2018.

·      Advanced programs to identify novel therapeutic targets on toxic strains of the protein Tau for AD, and on protein TDP43 for ALS and FTD;

·      In February 2017, completed private placements providing total gross proceeds of approximately $2,700,000;

·      Appointed Mr. Anthony Giovinazzo to the Board of Directors.

·      Announced Mr. Daniel Geffken to the position of Chief Financial Officer.

 

Financial Results

Results of Operations – Three months ended March 31, 2017 and 2016

The net loss for the three months ended March 31, 2017 was $1,372,203 compared to a net loss of $670,150 for the three months ended March 31, 2016. The increased loss in the current period reflects the costs associated with operating the Company’s AD therapeutics program, supporting its patent portfolio, associated general corporate expenditures and higher stock-based compensation.  

 

Revenues for the three months ended March 31, 2017 and 2016 were nominal and relate to legacy technologies.  For the three months ended March 31, 2017 the Company recognized $658 in royalty revenue related to its preclinical AD diagnostic assay as compared to $2,486 for the three months ended March 31, 2016. 

Research and development expenses for the three months ended March 31, 2017 were $740,670 as compared to $361,484 in the three months ended March 31, 2016.    Costs are higher in the current period due to higher research program costs for the AD therapeutics program and higher stock-based compensation. 

General and administrative expenses for the three months ended March 31, 2017 were $629,792 as compared to $304,868 in the three months ended March 31, 2016.  The increased expenditures in the current period reflect higher investor relations expenses, higher salaries related to expansion of the senior management team, higher professional fees, and higher stock-based compensation. 

 

Outlook

The Company’s priority for 2017 is to actively pursue development of precision medicine therapeutics for AD and ALS. ProMIS will focus on progressing PMN 310, its lead development product, to IND submission anticipated by the end of 2018.

The Company will continue to expand its Intellectual Property (IP) estate relating to novel epitope targets on misfolded strains of proteins and Tau for AD and on misfolded strains of protein TDP43 for ALS and frontotemporal dementia (FTD). The Company’s complementary proprietary platform technologies, ProMISTM and Collective Coordinates, will be used to identify and confirm such novel targets.

Given the Company’s robust IP estate relating to misfolded SOD1 in ALS and the recently announced program to identify novel ALS therapeutic targets on toxic strains of the protein TDP43, ProMIS Neurosciences is actively seeking a collaborative development partnership in this field.

 

About ProMIS Neurosciences, Inc.

 

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

 

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences aims to develop novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS,

and currently has a preclinical monoclonal antibody therapeutic against this target.

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For further information, please consult the Company's website at:

www.promisneurosciences.com

 

Follow us on Twitter
Like us on LinkedIn

 

cbealamaro@streetwisereports.com

 

or contact

 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com



ProMIS Neurosciences, Inc.

NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE

 

ProMIS Neurosciences to announce results in a presentation at the 2017 American Association of Neurology annual meeting

  

TORONTO, Ontario – April 27, 2017 – ProMIS Neurosciences (“ProMIS” or the “Company”, TSE ticker PMN.TO), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced it will present results on its recent Alzheimer’s disease (AD) therapeutic developments on Friday, April 28th at the 2017 annual meeting of the American Academy of Neurology (AAN), held in Boston, MA, from April 22-28.

 “Based on our results presented at this year’s AAN annual meeting we anticipate ProMIS monoclonal antibodies (mAbs), selectively targeting toxic forms of Amyloid beta (Aβ), will demonstrate a ‘best in class’ product profile for treatment of AD”, stated Dr. Elliot Goldstein, ProMIS President and CEO. “Indeed, by virtually no binding to Aβ monomer, ProMIS mAb products should allow improved efficacy by avoiding targeting of this abundant, non-toxic form of Aβ. Similarly, by not targeting plaque which is associated with neurovascular edema (‘brain swelling’), a dose limiting adverse event, we anticipate improved safety and tolerability for our products”. 

The presentation, entitled Achieving the optimal profile for Alzheimer’s immunotherapy: Rational generation of antibodies specific for toxic Aβ oligomers is a poster authored by Dr. Steven Plotkin (et al.), the Company’s Chief Physics Officer and presented by Dr. Johanne Kaplan, ProMIS Chief Development Officer. Using one of the Company’s unique, proprietary discovery platforms, Collective Coordinates, the authors predicted five distinct epitopes (targets) on toxic pathogenic Aβ oligomers (prion-like forms of Aβ). Results of the predictive methodology indicate that these oligomer-specific epitopes are conformationally distinct, in other words shaped differently from the same primary sequences in either Aβ monomer or fibrils, the latter representing the main constituent of Aβ plaque.

The authors conclude that monoclonal antibodies generated by immunizing with the predicted conformational epitopes bind selectively to toxic Aβ oligomers, inhibit Aβ propagation (spreading) in vitro, bind preferentially to AD brain tissue and cerebrospinal fluid (CSF), show little or no reactivity to plaques in cadaveric AD brain and protect against Aβ toxicity in vitro. Furthermore, the Company’s lead product, PMN310, was shown to preserve cognitive function in a preclinical animal model evaluating short term memory retention (dual object recognition test).

  

About ProMIS Neurosciences, Inc.

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.  

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has three preclinical monoclonal antibody therapeutics against this target.

The information in this release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For further information please consult the Company's website at:

www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

cbealamaro@streetwisereports.com

or contact

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com



ProMIS Neurosciences, Inc.

NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE

ProMIS Neurosciences announces results presented at the 13th International Conference on Alzheimer’s and Parkinson’s diseases held in Vienna, Austria

TORONTO, Ontario – April 12, 2017 – ProMIS Neurosciences (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announces results of its recent therapeutic developments presented at the 13th International Conference on Alzheimer’s (AD) and Parkinson’s diseases held in Vienna, Austria, from March 29 to April 2nd. This year’s conference was devoted to mechanisms, clinical strategies and promising treatments of neurodegenerative diseases.

“Results presented at the 13th International AD/PD conference confirmed ProMIS monoclonal antibodies (mAbs) selectively target five distinct epitopes on misfolded strains of toxic Amyloid beta (Aβ), without targeting Aβ monomer or plaque”, stated Dr. Elliot Goldstein, ProMIS President and CEO. “Prior AD clinical trials with mAbs targeting monomer (e.g. solanezumab) have been ineffective, due to target distraction, whereas mAbs targeting plaque (e.g. aducanumab) are associated with the dose limiting toxicity of brain swelling. By specifically targeting only the toxic forms of Aβ, we anticipate ProMIS mAbs will demonstrate a best in class product profile with respect to both efficacy and tolerabilty”.

ProMIS’ communication at the Conference, entitled Rational generation of Aβ oligomer-specific antibodies through computational identification of conformational epitopeswas an oral presentation and poster authored by Dr. Ebrima Gibbs (et al.), from the laboratory of ProMIS Chief Scientific Officer, Dr. Neil Cashman. The authors used the Company’s two proprietary computational algorithms (ProMIS and Collective Coordinates) to predict structurally integral misfolding of Aβ and the resulting five disease specific epitopes (targets for antibodies). ProMIS mAbs raised against each of these targets showed:

In addition, the Company’s lead mAb product PMN310, improved cognitive function in a preclinical animal model evaluating short term memory retention (dual object recognition test).

About ProMIS Neurosciences, Inc. 

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS. 

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique “precision medicine” approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has three preclinical monoclonal antibody therapeutics against this target. 

The information in this release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

For further information please consult the Company’s website at: 

www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

cbealamaro@streetwisereports.com

or contact

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com



ProMIS Neurosciences, Inc.

NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE 

ProMIS Neurosciences announces overview of first quarter 2017 progress and outlook for near term value creation

Toronto, Ontario – March 30, 2017 – ProMIS Neurosciences (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, released today management’s review of the first quarter of 2017, which included a review of Q1 accomplishments, a status update on ongoing programs, and its outlook for near term value creation.

Key highlights of the quarterly update include:

—  Numerous studies underway and on track to further validate that ProMIS is building a ‘best in class’ portfolio of therapies targeting toxic, prion-like forms of Amyloid beta, a root cause of Alzheimer’s;

—  Results announced in January for lead product PMN310 showed prevention of short term memory loss in a well-validated mouse model. ProMIS’s other four monoclonal antibodies (mAbs) are undergoing evaluation in the same model, with results expected over the coming months;

—  PMN310 on track for IND submission (clinical trial initiation) in late 2018;

—  Cohort study underway, evaluating presence and prevalence of ProMIS mAb targets in cerebrospinal fluid (CSF) and blood from Alzheimer’s patients, with initial readout expected in the coming months;

—  Diagnostics development underway and on track; goal is to create diagnostics to detect different toxic oligomer strains of Amyloid beta in both CSF and blood;

—  Discovery programs for TDP43 and Tau, two highly valued targets in neurodegenerative disease and dementia, on track with confirmation of targets and patent submissions expected soon.

“2017 is shaping up to be a very important year for ProMIS, and the year is off to a great start.   All our programs are progressing well, and external events continue to support our scientific strategy”, said Eugene Williams, Executive Chairman.

“Recently announced results of major clinical trials with competitor products in Alzheimer’s strongly support ProMIS’ differentiation”, stated ProMIS President and CEO, Dr. Elliot Goldstein. “We remain very confident that our mAb programs focused on selectively targeting the toxic, prion-like forms of Amyloid beta will lead to ‘best in class therapy’ and significant value creation”.

The Company overview of first quarter 2017 progress and outlook for the future is available on the ProMIS Neurosciences website at: http://bit.ly/2mQj48l

 

About ProMIS Neurosciences, Inc.

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.  

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS,

and currently has three preclinical monoclonal antibody therapeutics against this target.

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For further information please consult the Company's website at:

www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

Join us on 8020Connect

or contact

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

 

Elliot.goldstein@promisneurosciences.com



ProMIS Neurosciences, Inc.

NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE

ProMIS Neurosciences announces presentation and expert panel participation at the Neuroscience Biopartnering and Investment Forum held on March 27, 2017 at the New York Academy of Sciences 

Toronto, Ontario – March 28, 2017 – ProMIS Neurosciences (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its participation in the 2nd Annual Neuroscience Biopartnering and Investment Forum conference organized by Sachs Associates and held at the New York Academy of Sciences on March 27, 2017.

ProMIS Executive Chairman, Eugene Williams, presented an update and overview on the company’s rapid progress and future outlook, and also contributed as a member of the expert panel entitled “Advances in Alzheimer’s Disease”.

“Following on from the Company’s successful fund raise announced in February of this year, ProMIS will focus on progressing the development of its antibody program targeting toxic, prion-like forms of Amyloid beta, a root cause of Alzheimer’s. Our lead development product, PMN310, is on track for IND submission at the end of 2018”, stated Williams. “Furthermore, there is a substantial body of evidence from prior clinical trials in AD that targeting specifically the toxic, prion-like strains of Amyloid beta, while avoiding targeting of Amyloid beta monomer and plaque, will lead to best in class disease modifying therapy”.

 The Company overview presented at the meeting is available on the ProMIS Neurosciences website at: http://bit.ly/2na9QPl

  

About ProMIS Neurosciences, Inc.

 

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has three preclinical monoclonal antibody therapeutics against this target.

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For further information please consult the Company's website at:

www.promisneurosciences.com

 

Follow us on Twitter
Like us on LinkedIn

Join us on 8020Connect

or contact

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

 

Elliot.goldstein@promisneurosciences.com



ProMIS Neurosciences, Inc.

NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE

 

ProMIS Neurosciences Announces Appointment of Daniel Geffken as Chief Financial Officer

 

Toronto, Ontario – March 22, 2017 – ProMIS Neurosciences (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that it has appointed Daniel E. Geffken to the position of Chief Financial Officer.

“We are pleased to welcome Daniel Geffken as his broad skill set and experience will contribute significant value to the ProMIS team,” said Eugene Williams,  ProMIS Executive Chairman. “In particular, Daniel’s well–recognized expertise in building science-based companies and track record in strategic fundraising are key capabilities that fit perfectly with the developing needs of ProMIS”.

Daniel Geffken is a Founding Managing Director of Danforth Advisors, LLC and brings more than 25 years of experience in the life science industry to his work with ProMIS.

“I am delighted to join ProMIS, a rapidly developing company at the forefront of precision medicine treatments for neurodegenerative diseases, particularly Alzheimer’s disease and ALS,” said Geffken. “I look forward to working with the executive team to assist the company in achieving these important objectives”.

 

About Daniel Geffken

 Daniel Geffken is a Founding Managing Director of Danforth Advisors, LLC, a consulting firm providing finance, operations and strategic support to life science companies.  He brings more than 25 years of experience in the life science industry to his work with ProMIS, ranging from start-ups to publicly traded companies with $1 billion+ market capitalizations. He previously served as COO or CFO of four publicly traded and four privately held life science companies, in addition to his consulting clients. Daniel has been chief financial officer of Homology, Inc, GenePeeks, Inc., Transkaryotic Therapies, Inc., Cidara, Inc., Apellis, Inc. and Stealth BioTherapeutics, Inc.  He has raised more than $1 billion in equity and debt securities for life science companies. Daniel holds a B.S. from The Wharton School, University of Pennsylvania, and M.B.A. from Harvard Business School.

 

About ProMIS Neurosciences, Inc.

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS,

and currently has three preclinical monoclonal antibody therapeutics against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company's website at:

www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

Join us on 8020Connect

 or contact

 Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

 

Elliot.goldstein@promisneurosciences.com



ProMISTM Neurosciences, Inc.

 

NEWS RELEASE TSX: PMN

FOR IMMEDIATE RELEASE

 

ProMIS Neurosciences Announces  Fiscal 2016 Annual Results

 TORONTO, Ontario –March 15, 2017 – ProMIS Neurosciences, Inc. (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results for the year ended December 31, 2016, as well as the financial results for the fourth quarter.

 "ProMIS made significant progress on our Alzheimer’s disease (AD) program by identifying five therapeutic candidates with the ideal target profile of selectively binding to the neurotoxic prion-like forms of Amyloid beta (Aβ)” said Dr. Elliot Goldstein, ProMIS CEO. "We now look forward to advancing our lead product, PMN 310, as a potential best in class therapy for AD; to completing a cohort study to determine the prevalence of different prion strains in AD and to developing effective AD diagnostics for detection of toxic Aβ prion strains in cerebrospinal fluid (CSF) or blood.”

 ProMIS also announced two new drug development programs to identify novel therapeutic targets on Tau for AD, and TDP43 for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), representing additional opportunities to apply ProMIS complementary platform technologies.

 

Recent Corporate Highlights

·         Identified multiple therapeutic candidates during the screening stage of validation to be  developed as potential treatments for AD;

·         Successfully completed validation of five therapeutic candidates for AD that demonstrated the desired target profile of selective binding to cadaveric brain tissue extracts and cerebrospinal fluid (CSF) of AD patients without binding to plaque or monomer;

·         PMN 310 declared lead development product;

·         Initiated a CSF cohort study to determine the prevalence of different Aβ prion strains in AD;

·         Initiated programs to identify novel therapeutic targets on toxic strains of the protein Tau for AD, and on protein TDP43 for ALS and FTD;

·         Completed two non-brokered private placements providing total gross proceeds of approximately $4,200,000;

·         Appointed Dr. Johanne Kaplan, as Chief Development Officer;

·         Appointed Dr.  Richard Gregory and Mr. Anthony Giovinazzo to the Board of Directors.

 

Financial Results

Annual Results of Operations

The net loss for the year ended December 31, 2016 was $3,454,975 compared to a net loss of $2,120,954 for the year ended December 31, 2015. The increased loss in the current period reflects the costs associated with operating the Company’s Alzheimer’s therapeutics program, supporting its patent portfolio, and associated general corporate expenditures.   In the first half of the year ended December 31, 2015, the Company had closed its research facility in Mississauga Ontario and was undergoing a strategic review of its operations, hence expenses were significantly reduced.

Research and development expenses for the year ended December 31, 2016 were $1,865,507 as compared to $1,060,142 in the year ended December 31, 2015.    Costs are higher in the current period due to higher patent filings fees, research program costs for the company’s Alzheimer’s therapeutics program, including its research team, and antibody developments costs and validation studies, and offset slightly by lower stock option compensation.   Expenditures in the comparative period were significantly lower  due to cost saving measures while the Board of Directors was undergoing a strategic review of the Company’s operations.

General and administrative expenses for the year ended December 31, 2016 were $1,576,271 as compared to $946,765 in the year ended December 31, 2015.  The increased expenditures in the current period reflect mostly higher investor relations expenses, and higher stock-based compensation. 

Results of Operations – Three months ended December 31, 2016 and 2015

The net loss for the three months ended December 31, 2016 was $1,211,101 compared to a net loss of $699,785 for the three months ended December 31, 2015.

Research and development expenses for the three months ended December 31, 2016 were $696,279 as compared to $348,719 in the three-month period ended December 31, 2015. The increase in expenditures in the current period related mostly to the activity supporting the Company’s Alzheimer’s therapeutic program, specifically higher consulting fees related to its expanded research team, both internal and provided by the University of British Columbia, and by antibody development costs and related validation studies. 

General and administrative expenses for the three months ended December 31, 2016 were $512,561 as compared to $344,814 in the three months ended December 31, 2015. The increase in expenditures in the current period resulted mainly from increased investor relations activities.

Outlook

The Company’s priorities for the next year are to identify and develop precision medicine therapeutics for AD and ALS.

The Company will continue to expand its Intellectual Property (IP) estate relating to novel epitope targets on misfolded strains of proteins and Tau for AD and on misfolded strains of protein TDP43 for ALS and FTD. The Company’s complementary proprietary platform technologies, ProMISTM and Collective Coordinates, will be employed to identify and confirm such novel targets.

Using its proprietary discovery platform the Company raised monoclonal antibodies (“mAbs”) against five novel targets identified in its program for AD, and following in vitro and in vivo validation, declared PMN310 the lead product for development. ProMIS is looking forward  to completing final validation studies for the remaining therapeutic candidates  to enable their selection for further development.

Given the Company’s robust IP estate relating to misfolded SOD1 in ALS and the recently announced program to identify novel ALS therapeutic targets on toxic strains of the protein TDP43, ProMIS Neurosciences is actively seeking a development partnership in this field.

 About ProMIS Neurosciences, Inc.

 The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

 ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS,

and currently has a preclinical monoclonal antibody therapeutic against this target.

 The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please consult the Company's website at:

www.promisneurosciences.com,

Follow us on Twitter
Like us on LinkedIn

or contact

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

 

Elliot.goldstein@promisneurosciences.com



 

ProMIS Neurosciences, Inc.

 

NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE 

 

ProMIS Neurosciences announces appointment of Anthony Giovinazzo to its Board of Directors 

 

Accomplished biotech leader joins ProMIS Board of Directors  

 

TORONTO, Ontario – March 2, 2017 – ProMIS Neurosciences (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the appointment of Anthony J. Giovinazzo, MBA, to its Board of Directors, effective immediately. 

 

“I first met Anthony over twenty years ago, working together on an Alzheimer’s diagnostics opportunity” stated Eugene Williams, ProMIS Executive Chairman. “He and I have been talking about a shared commitment to making a difference in Alzheimer’s for a long time.   After the outstanding job that Anthony did at Cynapsus, for both Parkinson’s patients and shareholders, he has many alternatives.  We are thrilled that he has chosen to apply his talents and energy to ProMIS”. 

 

Anthony Giovinazzo is currently  President and CEO of Sunovion CNS Development Canada ULC. As President and CEO of Cynapsus Therapeutics from 2009 through 2016 he led the successful purchase of  Cynapsus by Sunovion Pharmaceuticals, a member of the Dainipon Sumitomo Pharma group of Japan. At Cynapsus, Anthony led the successful development of APL 130277 (a sublingual strip of apomorphine) through to late stage Phase 3 studies and was responsible for Cynapsus up-listing from the TSX Venture exchange to the TSX and then the NASDAQ. 

 

“I am delighted to join the Board of Directors of ProMIS Neurosciences,” stated Mr. Giovinazzo. “Having devoted most of my career to the development and commercialization of therapies for neurodegenerative disease, I look forward to leveraging my experience   to support the Company as it develops innovative, precision medicine therapeutics for Alzheimer’s disease and ALS”. 

 

About Anthony Giovinazzo, MBA.

 

Anthony J. Giovinazzo has over thirty-eight years of professional experience. His first seven years were spent as an international corporate tax specialist primarily in multinational conglomerates. Over the subsequent eight years Anthony worked in Fortune 100 investment banking and private equity. For the last twenty-three years he worked exclusively on the discovery, development and commercialization of neurodegenerative disease therapeutics. His primary areas of focus have been Alzheimer’s, Parkinson’s and neuropathic pain.

 

Since October 2016 he has been the President and CEO of Sunovion CNS Development Canada ULC., a successor company to Cynapsus Therapeutics Inc., which was purchased by Sunovion Pharmaceuticals Inc., a member of the Dainipon Sumitomo Pharma group of companies of Japan. He was President, CEO and a Director of Cynapsus Therapeutics Inc. from 2009 to 2016 and was one of the three original inventors and patent holders of the Cynapsus Parkinson’s focussed technology. Under his leadership the company successfully developed APL 130277 (a sublingual strip of apomorphine for OFF episodes) through to late stage Phase 3 studies. In addition, Anthony led the up-listing of Cynapsus from the TSX Venture exchange to the TSX and then the NASDAQ, attracting bulge bracket investment banks and some of the largest institutional life science investors in the USA. The sale of Cynapsus to Sunovion in 2016 resulted in a 120% premium to market price (CDN$841 million) via an all cash M&A transaction.

 

Mr Giovinazzo is the co-author of several peer reviewed papers and author of several papers on strategic and financing issues in the biopharmaceutical industry. He was a finalist in the E&Y Entrepreneur of the Year (2014) for Ontario Canada. He is a Chartered Director and Audit Committee Certified, both from The Directors College, a degree granting affiliate of Mc Master University, Hamilton Canada. He also has completed the Leadership and Strategy in Pharmaceuticals and Biotech, in 2006 from Harvard Business School, Boston, MA; a Masters of Business Administration from IMD, Geneva Switzerland in 1986; Graduate Certificate Studies in Canadian Law Osgoode Hall Law School, York University, Toronto, in 1984; and his Bachelor of Arts in Economics and Accounting at McMaster University in 1978.   

 

About ProMIS Neurosciences, Inc.

 

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.  

 

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.  

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  

 

For further information please consult the Company's website at:

 

www.promisneurosciences.com
Like us on LinkedIn

or contact

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

 

Elliot.goldstein@promisneurosciences.com

 



ProMIS Neurosciences, Inc.

NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE

NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

 

PROMIS NEUROSCIENCES SUCCESSFULLY COMPLETES CDN$2.7 MILLION PRIVATE PLACEMENT

TORONTO, Ontario –February 23, 2017– ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) is pleased to announce that it has completed its non-brokered private placement in the amount of CDN$2,719,813.

 

The net proceeds of the private placement will be used to (a) further advance the Company’s Alzheimer disease (AD) portfolio, including development of its lead product PMN 310, and conducting a cohort study to determine the prevalence of different prion strains in AD (b) initiate development of effective AD diagnostics for detection of toxic prion strains in cerebrospinal fluid (CSF) or blood (c) develop ProMIS’ Tau and TDP43 assets for dementias and ALS (d) continue efforts toward partnering ProMIS’ ALS assets and (e) support general working capital expenses, including those related to building and maintaining its intellectual property portfolio.

Pursuant to the private placement, ProMIS issued a total of 18,757,331 units (the “Units”) at $0.145 per Unit in two closings raising gross proceeds of CDN$2,719,813, with 15,848,863 Units being issued in the first closing (as announced on Feb. 13, 2017) and the balance in the second closing.  Each Unit issued consisted of one common share of the Company and one-half of a common share purchase warrant, with each whole warrant being exercisable into one common share at a price of $0.20 per share for 36 months from the issue date.  Directors of the Company purchased a total of 690,000 units or CDN$100,050 of the placement.

All securities issued are subject to a four month hold period under applicable provincial securities laws in Canada. In connection with the second closing, ProMIS will pay finder’s fees of $5,605.70 and will issue 24,500 finder warrants, with each finder warrant exercisable into one common share at a price of $0.17 per share for 36 months from the issue date.

“The proceeds from this private placement will allow us to continue the significant progress the Company has made over the past eighteen months," stated Eugene Williams, ProMIS Executive Chairman. “ProMIS is positioned to generate a compelling body of evidence demonstrating its antibody therapeutics that selectively target toxic prion-like forms of Amyloid beta will be best in class, and therefore hold the potential to transform the AD treatment paradigm. In addition, results from the Cohort study could revolutionize the approach to treating AD by supporting the concept that personalized medicine is critical for most effective therapy”.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About ProMIS Neurosciences, Inc.

 

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS,

and currently has a preclinical monoclonal antibody therapeutic against this target.

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For further information please consult the Company's website at:

www.promisneurosciences.com

 

Follow us on Twitter
Like us on 
LinkedIn

 

NATIONAL Equicom

Abby Garfunkel

Tel. 403-218-2887

agarfunkel@national.ca

 

 

or contact

 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com



 

ProMIS Neurosciences, Inc.

 

NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE

 

ProMIS Neurosciences issues white paper entitled “Results from recent Alzheimer’s disease trials validate the ProMIS approach” 

 

TORONTO, Ontario – February 22, 2017 – ProMIS Neurosciences (“ProMIS” or the “Company”), a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced it has issued a scientific white paper entitled “Results from recent Alzheimer’s disease trials validate the ProMIS approach.” This is one of a series of commentaries from ProMIS’s scientific team offering insight into the Company’s product portfolio and Alzheimer’s disease (AD) science in the popular press.

 

The white paper discusses the recent late-stage clinical trial failures of Eli Lilly’s solanezumab, a monoclonal antibody (mAb) mainly targeting Amyloid beta (Ab) monomers, and Merck’s verubecestat, a small molecule BACE inhibitor that blocks the cleavage of amyloid precursor protein, thereby significantly reducing the formation of Ab monomers in the brain.

 

Commenting on the results of the failed clinical trials, Dr. Johanne Kaplan, ProMIS Chief Development Officer stated, “Both approaches, which mainly target Ab monomers failed to show clinically significant cognitive benefit as they failed to engage toxic Ab oligomers, which propagate in a prion-like manner and are the primary drivers of neurodegeneration and cognitive decline in AD patients.” 

 

Conversely, Biogen’s monoclonal antibody aducanumab, which binds Ab oligomers and plaque, reduced cognitive decline in a Phase 1b trial. Binding to plaque however, was associated with dose-dependent toxicity (brain edema, or ARIA-E), which limits the therapeutic window for this antibody.  

 

The white paper concludes that human clinical data to date are supportive of the ProMIS approach of selectively targeting soluble toxic Aβ oligomers. “We believe our approach will lead to best in class therapy as selectively targeting the toxic prion-like Aβ oligomers maximizes efficacy by avoiding off target binding to non-pathogenic Aβ monomers, and decreases the risk of edema and vascular adverse events associated with plaque binding,” stated Dr. Elliot Goldstein, ProMIS President & CEO.

 

About ProMIS Neurosciences, Inc.

 

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

 

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS,

 

and currently has a preclinical monoclonal antibody therapeutic against this target.

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For further information, and to access the white paper, please consult the Company's website at:

 

www.promisneurosciences.com

 

 

Follow us on Twitter
Like us on LinkedIn

 

 

 

NATIONAL Equicom

 

Abby Garfunkel

 

Tel. 403-218-2887

 

agarfunkel@national.ca

 

or contact

 

Dr. Elliot Goldstein

 

President and Chief Executive Officer, ProMIS Neurosciences Inc.

 

Tel. 415 341-5783

 

Elliot.goldstein@promisneurosciences.com

 



NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE

 

NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

 

PROMIS NEUROSCIENCES SUCCESSFULLY COMPLETES FIRST CLOSING AND INCREASES PRIVATE PLACEMENT TO CDN$2,700,000

 

TORONTO, Ontario –February 13, 2017– ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) is pleased to announce that it has completed a first closing of its non-brokered private placement in the amount of CDN$2,298,085.02 which, as a result of over-subscriptions, is greater than the CDN$2,030,000 offering amount announced on February 2, 2017.

 

To accommodate further demand, ProMIS is increasing the offering to a maximum of CDN$2,700,000 for a maximum of 18,620,700 units (the “Units”) at $0.145 per Unit. The Company plans to close the balance of the increased offering by February 17, 2017.

 

In the first closing on February 10, 2017, the Company issued 15,848,863 Units, each consisting of one common share of the Company and one-half of a common share purchase warrant. Each whole warrant is exercisable into one common share at a price of $0.20 per share for 36 months. Also, in connection with the first closing, ProMIS paid finder’s fees of $ $56,170 and will issue 311,379 finder warrants, each exercisable into one common share at a price of $0.17 per share for 36 months.

 

All securities issued are subject to a four month hold period under applicable provincial securities laws in Canada. The offering is subject to customary conditions, including TSX approvals.

 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

 

About ProMIS Neurosciences, Inc.

 

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

 

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMISand Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular  surface  of  misfolded  proteins.  Using  this  unique  "precision  medicine"  approach, ProMIS

Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to  be  materially  different from  those  implied  by  statements herein, and  therefore  these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company's website at: www.promisneurosciences.com

Follow us on Twitter Like us on LinkedIn

 

NATIONAL Equicom

Abby Garfunkel Tel. 403-218-2887

garfunkel@national.ca

 

or contact

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc. Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com

 



ProMIS Neurosciences, Inc.

NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE

NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES



PROMIS NEUROSCIENCES ANNOUNCES PRIVATE PLACEMENT

TORONTO, Ontario –February 6, 2017– ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) today announced that it is offering, on a private placement basis, up to 14,000,000 units (the “Units”) at price of CDN$0.145 per Unit (the “Offering”) for proceeds of up to approximately CDN$2,030,000.

Each Unit will consist of one common share of the Company and one-half of a common share purchase warrant, with each whole warrant exercisable into one common share at a price of $0.20 per share for 36 months. The net proceeds of the Offering will be used to (a) further advance the Company’s Alzheimer disease (AD) portfolio, including development of its lead product PMN 310, and conducting a cohort study to determine the prevalence of different prion strains in AD (b) initiate development of effective AD diagnostics for detection of toxic prion strains in cerebrospinal fluid (CSF) or blood (c) develop ProMIS’ Tau and TDP43 assets for dementias and ALS (d) continue efforts toward partnering ProMIS’ ALS assets and (e) support general working capital expenses, including those related to building and maintaining its intellectual property portfolio.

“During the past year, we have made significant progress developing ProMIS’ precision medicine program for Alzheimer’s disease, which specifically targets toxic, prion-like forms of Amyloid beta,” commented Dr. Elliot Goldstein, ProMIS President and CEO. “With the anticipated proceeds of this private placement we look forward to continued progress for our AD therapeutic antibody portfolio, particularly of PMN 310, our lead development product.”

All shares issued will be subject to a four month hold period under applicable provincial securities laws in Canada. Closing of the Offering is subject to receipt of TSX acceptance. The Company will pay finders’ fees and issue finder warrants on a portion of the Offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

 

About ProMIS Neurosciences, Inc.

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique “precision medicine” approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release contains certain forward-looking information, notably the use of proceeds. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For further information please consult the Company's website at:

www.promisneurosciences.com

 

Follow us on Twitter
Like us on LinkedIn

 

NATIONAL Equicom

Michael Moore Abby Garfunkel

Tel. 858-886-7813 Tel. 403-218-2887

mmoore@national.ca agarfunkel@national.ca

 

or contact

 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

Elliot.goldstein@promisneurosciences.com